New hope for containing advanced breast cancer
NCT ID NCT05982678
First seen Jan 08, 2026 · Last updated Apr 21, 2026 · Updated 14 times
Summary
This study is testing a targeted drug called trastuzumab-deruxtecan (T-DXd) for people with HER2-positive breast cancer that has spread to only 1-5 other sites in the body. The goal is to see if this drug, given before and after local treatments like surgery or radiation, can lead to deep, long-lasting remission. It aims to fill a gap in care for patients whose cancer has spread but is still limited enough to potentially be treated with a goal of long-term control.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2-POSITIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-••••
Locations
-
Antoni van Leeuwenhoek
RECRUITINGAmsterdam, Netherlands
Contact
Contact
Contact
Conditions
Explore the condition pages connected to this study.